Recent developments include funding secured for an expanded access program for leronlimab in breast cancer, key consultant appointments in oncology and hepatology, and submission of revised clinical trial protocols to the FDA.

• CytoDyn secured funding to launch an expanded access program for leronlimab in breast cancer [N1].
• The company appointed Richard Pestell as lead consultant in oncology [N2].
• Melissa Palmer was appointed as lead consultant in hepatology [N6].
• CytoDyn submitted a revised HIV clinical trial protocol to the FDA and started a glioblastoma pre-clinical study [N8].

CytoDyn has advanced its clinical pipeline with ongoing Phase II trials and pre-clinical studies, supported by recent funding to expand access programs for leronlimab in breast cancer. The appointment of specialized consultants in oncology and hepatology may enhance clinical development and regulatory strategy. The extension of convertible note maturities and reduction in interest rates provide some financial flexibility. Clinical and regulatory progress could address unmet medical needs in multiple indications, potentially creating value for stakeholders.

The company faces significant liquidity challenges, with cash and current liabilities indicating a strained financial position. Continued operating losses and a substantial accumulated deficit raise concerns about its ability to sustain operations without additional capital. Financing through equity and debt may dilute existing shareholders and impose operational restrictions. The outcome of ongoing legal settlements and regulatory approvals remains uncertain, posing risks to business continuity. Challenges in securing sufficient funding or regulatory clearance could materially impair the company's prospects.

CytoDyn's moat is primarily based on its proprietary drug candidate leronlimab, which targets the CCR5 receptor and is being developed for multiple indications including oncology and HIV. The company's clinical trial progress and regulatory interactions provide some barriers to entry. However, as a clinical-stage biotech firm without approved products, its competitive advantage depends heavily on successful clinical development, regulatory approval, and commercialization, which remain uncertain. The company also faces dilution risks from ongoing financing activities and potential legal contingencies.

• Liquidity Risk: As of February 28, 2026, CytoDyn had $15.7 million in cash against $50.4 million in current liabilities, with a current ratio of 0.37, indicating potential difficulties in meeting short-term obligations without additional financing [S1].
• Regulatory Risk: The company’s ability to commercialize leronlimab depends on obtaining regulatory approvals, which are subject to clinical trial outcomes and regulatory agency decisions [S1].
• Financing and Dilution Risk: CytoDyn plans to finance operations through equity and debt offerings, which may dilute existing shareholders and include covenants restricting operations [S1].
• Legal and Settlement Risk: The company is involved in Securities Class Action litigation with a settlement agreement in principle; failure to finalize the settlement could materially harm financial condition and operations [S1].
• Operational Risk: The company’s research and development expenses are significant and subject to variability based on clinical trial activities and strategic decisions [S1].

• CytoDyn Inc. is a clinical-stage biotechnology company focused on the development and commercialization of leronlimab, a CCR5 antagonist, for multiple indications including oncology, HIV, and inflammation.
• The company is conducting clinical trials including a Phase II trial of leronlimab in relapsed/refractory micro-satellite stable colorectal cancer and has initiated pre-clinical studies in glioblastoma.
• CytoDyn has secured funding to launch an expanded access program for leronlimab in breast cancer [N1].
• The company has appointed Richard Pestell as lead consultant in oncology [N2] and Melissa Palmer as lead consultant in hepatology [N6].
• CytoDyn submitted a revised HIV clinical trial protocol to the FDA and started a glioblastoma pre-clinical study [N8].
• As of February 28, 2026, CytoDyn had approximately $15.7 million in cash and cash equivalents and $50.4 million in current liabilities, resulting in a current ratio of 0.37 and a cash ratio of 0.31, indicating liquidity constraints [S1].
• The company reported a net loss of $4.69 million for the three months ended February 28, 2026, and an accumulated deficit of approximately $920.6 million as of that date [S1].
• Operating expenses increased primarily due to higher clinical trial costs and legal settlement revaluation related to Securities Class Action lawsuits [S1].
• CytoDyn has convertible notes with extended maturity dates to April 2029, with monthly payments in shares of common stock and a reduced interest rate of 5% [S1].
• The company plans to finance future operations primarily through the sale of equity and debt securities, which may result in dilution to stockholders and may include restrictive covenants [S1].
• There is substantial doubt about the company's ability to continue as a going concern without additional capital and regulatory approvals [S1].